Business Context and Reporting Period
This Form 8-K, dated September 24, 2018, reports on Cerecor Inc. (the "Company"), a Delaware corporation. The filing details the entry into and subsequent completion of a definitive merger agreement with Ichorion Therapeutics, Inc. ("Ichorion"). The transaction closed on September 25, 2018, with Ichorion surviving as a wholly-owned subsidiary of Cerecor.
Key Financial Metrics and Transaction Terms
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, or debt levels for the reporting period. The primary financial data relates to the acquisition consideration:
- Equity Consideration: 5,798,735 shares of Cerecor Common Stock (subject to working capital adjustments).
- Contingent Consideration: Up to $15,000,000 in future development milestones, payable in cash or stock.
- Pro Forma Data: The filing states that pro forma financial information will be filed in an amendment within 71 days; no current values are provided.
Material Changes
The material change reported is the acquisition of Ichorion Therapeutics, Inc. This transaction expands Cerecor's portfolio through the merger of Ichorion into the Company. The issuance of shares for this transaction was unregistered, relying on Section 4(a)(2) of the Securities Act of 1933.
Outlook, Risks, and Contingencies
Management Commentary: The Company issued a press release on September 25, 2018, announcing the acquisition. The Merger Agreement includes customary representations, warranties, and indemnification provisions.
Risks and Contingencies:
- Future Payments: The Company is exposed to potential future cash or stock outflows of up to $15 million contingent on development milestones.
- Working Capital Adjustment: The final share count is subject to adjustment based on Estimated Working Capital.
- Financial Reporting: Financial statements of the acquired business and pro forma information are not yet available and are pending future filing.
Investor Verification Checklist
- Verify the final share count after the Estimated Working Capital adjustment is calculated.
- Review the specific development milestones required to trigger the $15,000,000 contingent payment.
- Monitor the upcoming amendment to this 8-K for the required financial statements of Ichorion and pro forma financial information.
- Confirm the dilution impact of the 5,798,735 shares issued on existing shareholders.